



February 12, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub: Press release

**Ref: HealthCare Global Enterprises Limited (“the Company”) (NSE Scrip Code:
HCG/ BSE Scrip Code: 539787)**

Dear Sir/Madam,

Please find enclosed herewith the communication being released to the Press regarding the investment of Quadria Capital in Strand Life Sciences Private Limited.

Request you to take this on record.

For HealthCare Global Enterprises Limited

SUNU MANUEL Digitally signed by SUNU MANUEL
Date: 2018.02.12 11:45:07 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above



February 12, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub: Press release

**Ref: HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/
BSE Scrip Code: 539787)**

Dear Sir/Madam,

Please find enclosed herewith the communication being released to the Press regarding the investment of Quadria Capital in Strand Life Sciences Private Limited.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer



Encl: as above

Quadria Capital to Invest in Strand Life Sciences

***Investment to fund the build out of integrated platform
dedicated to next generation precision medicine***

Bengaluru, India, February 12, 2018: HealthCare Global Enterprises Ltd. (“HCG”) today announced that Quadria Capital a leading Asian healthcare focused private equity investor has made an investment in Strand Life Sciences Pvt. Ltd. (“Strand”). The investment follows the previously announced combination of Triesta Sciences, a unit of HCG, and Strand, creating India’s leading specialized diagnostics player.

The investment by Quadria will fund the strategic expansion of Strand and the build out of a unique integrated platform dedicated to next generation precision medicine. Strand today has end-to-end capabilities spanning proprietary analytics, genomic technologies, translational research and a network of laboratories offering a comprehensive menu of tests. Strand is now well positioned to grow into Asia’s leading, integrated, specialised diagnostic company, and a leading provider of bioinformatics and research services worldwide.

Quadria Capital Managing Partner and Co-Founder Dr. Amit Varma, said: “The demand for specialized diagnostics has been rising rapidly across the region. With diagnostics moving beyond just identification of infections to becoming an integral part of management and therapy, we see a huge potential in this area. Quadria is very excited to partner with Strand in this unique diagnostic platform that provides a potent combination of world class bio-informatics, genomics research, and integrated specialised diagnostics.”

Dr. BS Ajaikumar, Chairman and CEO of HCG, said: “The future of medicine is personalised, precision and preventive. We are excited to convert our long-standing associations with Quadria and the Strand founders into a partnership that will offer the most comprehensive set of diagnostic technologies and focus on redefining precision medicine.”

Dr. Ramesh Hariharan, Co-Founder and CEO of Strand, said “Given their deep operating knowledge and experience of building healthcare businesses in Asia, the partnership with Quadria and HCG will help launch Strand into its next phase of growth and into an era where data analytics and molecular measurements together change diagnosis and treatment paradigms.”

Commenting on the announcement, industry veteran **Dr. Kiran Mazumdar-Shaw, Biocon, Chairman,** said: “Strand’s partnership with Triesta is an inflection point which I am confident will drive its future into the fast growing segment of genomic led onco-diagnostics. This merger has attracted a significant investment from Quadria Capital which endorses the credibility of Strand’s evolving business strategy.”

About HealthCare Global Enterprises Ltd.:

HealthCare Global Enterprises Ltd., headquartered in Bengaluru is a leading speciality healthcare provider with a focus on cancer care and reproductive medicine. Under the HCG brand, the company operates 20 comprehensive cancer centers across India and Africa, and has brought advanced cancer care to the doorstep of millions of people. “Milann”, India’s top ranked network of fertility centres is a subsidiary of HCG. **For further information,** visit www.hcgel.com or **contact:** investors@hcgoncology.com

About Strand Life Sciences Pvt. Ltd.:

Strand is a global leader bioinformatics and precision medicine diagnostics, aimed at empowering cancer care and enabling diagnosis of inherited diseases. Strand’s customers include leading global life science platform technology companies, research labs, as well as oncologists, paediatric specialists, geneticists and hospitals. **For further information,** visit www.strandls.com or **contact:** shakun@strandls.com

About Quadria Capital:

Quadria Capital is an independent healthcare focused private equity firm with assets under management exceeding US\$ 1.5 billion and investments in 18 companies across the Asia-Pacific region. Quadria focuses on partnering with promising regional healthcare companies and, with its active investment strategy, help them grow into regional leaders, while creating and delivering outstanding returns to its investors. For more information, visit www.quadriacapital.com